Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Replacement Half Year Report

30 Sep 2025 13:09

RNS Number : 4541B
Ovoca Bio PLC
30 September 2025
 

The tables in the "Half-year Report" announcement released on 30 September 2025 at 7am under RNS No 3030B were unclear and accordingly the announcement has been updated so that readers can access the tables via a pdf link now contained in the announcement.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Ovoca Bio PLC

30 September 2025

 

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

Interim Results for the six months ended 30 June 2025

 

Dublin, Ireland, 30 September 2025 - Ovoca Bio announces its interim financial statements and report covering the six-months ending 30 June 2025.

 

Please click on the following link to view the full Half Year Report and extracts are set out at the end of this announcement:

 

http://www.rns-pdf.londonstockexchange.com/rns/4541B_1-2025-9-30.pdf

 

CEO Statement

Today we have published Ovoca's financial statements covering the six-month period to the end of June 2025, which I encourage all stakeholders to read. On 7 May 2025 the Company entered into a conditional Letter of Intent ("LOI") to acquire 100% of Tadeen International Limited ("Tadeen"), a UK-registered company, which indirectly owns 100% of a portfolio of mineral exploration licenses in Morocco prospective for Copper and Silver (the "Proposed Acquisition"). The team at Ovoca has been working to complete the Proposed Acquisition and in due course further announcements will be made as we finalize the acquisition of Tadeen.

 

As at 30 June 2025, the Company had cash and cash equivalents amounting to €1,526 million ($ 1,788 million) and we will continue to carefully manage our financial resources. The costs incurred during the period relate to the costs of work in relation to the Proposed Acquisition along with corporate costs.

 

I would like to thank the management team of the Company and the Board of Directors for their support.

 

End

 

For further information:

 

Ovoca Bio plc

Tim McCutcheon (Chief Executive Officer)

Tel +353 1 661 9819

info@ovocabio.com

 

Beaumont Cornish Limited (Nominated Adviser and Broker)

James Biddle/ Roland Cornish

Tel: +44 (0) 207 628 3396

 

Nominated Adviser Statement

 

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other person for providing the protections afforded to customers of Beaumont Cornish nor for advising them in relation to the transaction and arrangements described in the announcement or any matter referred to in it.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR URRURVSUKOAR
Date   Source Headline
29th Nov 20076:14 pmRNSDirectors Dealing
26th Nov 200711:35 amRNSIEX Notice
19th Nov 20077:02 amRNSEquity Fundraising
19th Nov 20077:02 amRNSOperational Update
29th Oct 20077:00 amRNSIEX Notice
19th Oct 20079:28 amRNSOperational Update & Placing
20th Sep 20078:00 amRNSAGM Resolutions Passed
14th Sep 20075:30 pmRNSIssue of Consideration Shares
14th Sep 20074:24 pmRNSInterim Results
13th Sep 20077:01 amRNSOperational Update
28th Aug 20077:00 amRNSAIM Rule 26
28th Jun 20072:47 pmRNSAGM Statement
8th Jun 20077:01 amRNSJoint Venture Agreement
30th May 20079:28 amRNSConsultancy Appointment
18th May 200712:58 pmRNSBrochure of Particulars
17th May 20077:01 amRNSOperational Update
8th Feb 20077:30 amRNSGoltsovoye Update
1st Dec 200610:14 amRNSAppointment of new CEO
2nd Nov 200610:56 amRNSDrilling Update
1st Nov 200610:27 amRNSIEX Notice
18th Oct 200612:23 pmRNSIssue of Equity
16th Oct 20067:00 amRNSDrilling Update
29th Sep 200610:05 amRNSInterim Results
21st Sep 20064:23 pmRNSChange in Holding
18th Sep 20064:49 pmRNSHolding(s) in Company
11th Sep 20062:17 pmRNSResult of AGM
11th Sep 20067:02 amRNSDrilling Report
1st Sep 20067:00 amRNSHolding(s) in Company
31st Aug 20064:00 pmRNSFurther re Director Appt
25th Aug 20063:28 pmRNSre: Norplat
25th Aug 20067:00 amRNSIEX Notice
22nd Aug 20065:45 pmRNSNotice of AGM
31st Jul 20066:25 pmRNSAward of Options
31st Jul 20064:17 pmRNSBoard Changes
10th Jul 20067:01 amRNSDrilling Report
23rd Jun 20065:28 pmRNSFinal Results
23rd Jun 20069:59 amRNSBankable Feasibility Study
21st Jun 20067:00 amRNSIEX Notice
20th Jun 20063:24 pmRNSExercise of Warrants
12th Jun 20062:59 pmRNSIEX Notice
12th Jun 20067:00 amRNSIEX Notice
7th Jun 200611:24 amRNSPlacing
7th Jun 200611:22 amRNSCompletion of Acquisition
24th May 20067:00 amRNSManagement Appointment
23rd May 200610:27 amRNSExploration Activity Update
18th May 20067:01 amRNSNotice of EGM
18th Apr 20067:01 amRNSAcquisition
27th Feb 20069:17 amRNSIncrease in Hldg in Norplat
14th Dec 20057:00 amRNSIEX Notice
30th Sep 200512:17 pmRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.